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ABSTRACT

METHODS

RESULTS

In order to determine whether succinate dehydrogenase (SDH) deficiency plays a role in sporadic, non-familial pituitary adenomas, we analyzed 80 pituitary adenomas for SDH deficiency
from patients without familial tumor syndromes or without known SDH deficiency-associated
neoplasms. SDH deficiency was determined by immunohistochemical (IHC) stains for SDHB
since the loss of any of the four SDH subunits results in the loss of SDHB expression. Three
pituitary adenomas showed complete loss of SDHB staining, and of these two also showed loss
of SDHA staining. We further characterized these adenomas by looking at Ki67, IGF1R, and 5hmC levels via IHC. SDHx-deficient (non-SDHA deficient) tumors had a Ki67 proliferation
index higher than non-SDH deficient pituitary tumors while SDHA-deficient tumors had Ki67
indices similar to non-SDH deficient tumors. IGF1R IHC staining was similar across all
subsets. All SDH-deficient subtypes showed a loss of 5-hydroxymethylcytosine nuclear IHC
staining. These findings suggest that SDH deficiency promotes tumorigenesis of pituitary
adenomas through accumulation of succinate resulting in changes in the epigenome,
specifically resulting in a hypermethylated state.

All SDH-deficient pituitary adenomas were described clinically as large. The two SDHA
deficient adenomas were also invasive, with one growing into the nasal sinuses and the other
extending into the cavernous sinus. Tissue was fixed in formalin and embedded in paraffin
blocks. 5 micron-thick sections of representative pituitary adenomas were punched out of these
blocks and assembled into tissue arrays with 40-45 samples per slide (Figure 2). Arrays were
analyzed by IHC for expression of SDHA, SDHB, Ki67, IGF1R, and 5-hmC by standard
methods (Figure 3).
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Figure 3: TMA1 after IHC staining for SDHB. A dark stain indicates presence of SDHB and thus functioning SDH. Light to no staining indicates
SDHB absence and by extension SDH deficiency.

The pituitary adenomas analyzed were from
patients without familial tumor syndromes or
without known SDH deficiency-associated
neoplasms. Of the 80 cases, 40 were females
and 40 were males. The mean age was 52.3
years old (range 14-85).
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Table 1: The Ki67 proliferation index reflects the number of cells actively in the cell cycle and may reflect growth rate and growth potenial of a tumor. The two SDHA-deficient pituitary adenomas had Ki67
proliferation indices similar to other non-SDH deficient pituitary adenomas. The SDHx-deficient pituitary adenoma (adenoma with a
defective B, C, or D subunit), on the other hand, had an abnormally
increased Ki67 proliferation index. IGF1R staining of SDH-deficient
adenomas was in the range of IGF1R staining of non-SDH deficient
adenomas (data not shown). Analysis of additional cases is necessary
to determine if these differences and similarities are accurate.
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Figure 16: IHC for 5-hmC in
SDH-deficient adenoma A showed loss of and decreased nuclear
staining of 5-hmC. The intact,
strong nuclear 5-hmC staining is
noted in intratumoral endothelial
cells. The loss of nuclear 5-hmC
in this pituitary adenoma suggests that SDH deficiency may
promote pituitary adenoma formation by altering the methylation of cytosine residues within
DNA and histone proteins.
Figure 18: IHC for 5-hmC in
SDH-deficient adenoma C showed loss of and decreased nuclear
staining of 5-hmC.

Figure 17: IHC for 5-hmC in
SDH-deficient adenoma B showed loss of and decreased nuclear
staining of 5-hmC.



B: SDH deficient, 5-hmCFigure 4: Tissue microarray one IHC for SDHB. A: 27 yo
male with a ‘large’ pituitary adenoma. B: 56 yo male with
an invasive pituitary adenoma.
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Figures 5 & 6: Note the absence of the normal granular mitochondrial stain for SDH in this tissue sample from a 56 yo male. The fibrovascular framework is responsible for the scattered positive staining.

CONCLUSIONS
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Figure 7 (8 & 9): Tissue microarray one IHC for SDHA.
B from the SDHB IHC also stained negatively for SDHA.
Control SDHA staining is similar to control SDHB staining (below) in its strength and pattern.

SDHAFigure 8: B from SDHB IHC showing no SDHA.
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Figure 9: Control, non-SDH deficient SDHA IHC.

SDH deficiency may account for tumorigenesis in approximately 3.8% of sporadic pituitary adenomas.
Analysis of additional cases and molecular analysis will be a necessary next step to determine clinical differences in the behavior of SDH-deficient pituitary adenomas compared to non-SDH deficient pituitary adenomas, and the differences in behavior of the distinct subtypes (SDHA, SDHB, SDHC, and SDHD) of SDH-deficient pituitary adenomas.
Accumulation of cellular succinate resulting from SDH deficiency may cause pituitary adenomas due to abnormal DNA methylation, in particular hypermethylation.
Increased understanding of how SDH deficiency leads to pituitary adenomas may lead to development of targeted therapy for this subtype of pituitary adenoma with the ultimate goal of replacing surgical treatment.
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Figure 15: Positive nuclear
staining for 5-hmC by IHC is
noted in a pituitary adenoma
without SDH subunit deficiencies and intact SDH.
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Figure 1: The SDH complex.
There are four subunits: A, B, C,
and D. The A and B subunits are
hydrophilic and reside in the mitochondrial matrix. The C and D
subunits are hydrophobic and are
anchored in the inner mitochondrial membrane. The A subunit
serves as the binding site for succinate.
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Figure 2: H&E stain of tissue microarray one (TMA1) demonstrating
the format of these arrays. Empty locations represent areas of lost tissue.

Pituitary adenomas are relatively common neoplasms of the central nervous system found in
approximately 16% of the population. Among all intracranial neoplasms, pituitary adenomas
account for 10% of pathological new growths and are the most common neoplasms within the
sella. These tumors are categorized based on size, invasiveness, secretory capacity and
specificity, and are almost invariably derived from the adenohypophysis. Treatment is primarily
surgical.
The genesis of pituitary adenomas is still largely unresolved despite the association of these
tumors with syndromes that have known progenitor mutations. Several families with germline
mutations in the genes encoding SDH subunits have been associated with pituitary adenomas
and SDH deficiency is pro-oncogenic in a variety of other tumors, including extra-adrenal
paragangliomas, a subset of gastrointestinal stromal tumors, pheochromocytomas, and renal
cancers. Familial and genetic pituitary adenomas, however, account for only a small percentage
of all pituitary adenomas (~5%). While SDH-deficient tumors typically occur in the setting of
germline mutations, SDH-deficient tumors can occur sporadically.
The proposed mechanisms for tumorigenesis in SDH deficiency are loss-of-function mutations in or epigenetic silencing of SDH subunit genes that then cause the intermediate
metabolite succinate to accumulate. Succinate build-up can result in a pseudohypoxic state
within the cell which, through HIFα, upregulates expression of angiogenic factors and enzymes
that aid in cell survival. Another possible mechanism of tumorigenesis related to succinate
accumulation is inhibition of α-ketoglutarate-dependent dioxygenases, particularly the ten
eleven translocaton (TET) family of 5-methylcytosine (5mC) hydroxylases, which produces
epigenetic alterations. In particular, SDH-deficient tumors have elevated hypermethylation
compared to non-SDH deficient counterparts, suggested by the lower levels of 5hydroxymethylcytosine (5-hmC).
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Figures 13 & 14: Control, non-SDH deficient staining for SDHB is diffuse, dark, and granular.

